Universe Pharmaceuticals (UPC) Common Equity (2020 - 2025)

Universe Pharmaceuticals has disclosed Common Equity across 6 years of filings, most recently posting $56.1 billion for Q3 2025.

• Common Equity for Q3 2025 came in at $56.1 billion, up 23.35% year-over-year; the trailing twelve-month figure through Sep 2025 was $56.1 billion (up 23.35% YoY), and the FY2025 annual result was $56.1 billion, up 23.35% from the prior year.
• Common Equity came in at $56.1 billion for Q3 2025 at Universe Pharmaceuticals, up from $45.5 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $56.1 billion in Q3 2025 to a low of $47.0 million in Q3 2021.
• The 5-year median for Common Equity is $35.3 billion (2022), against an average of $33.0 billion.
• Across the five-year window, Common Equity soared 75083.64% in 2022 and decreased 20.83% in 2023, its largest moves.
• Universe Pharmaceuticals' Common Equity stood at $47.0 million in 2021, then jumped by 75083.64% to $35.3 billion in 2022, then decreased by 20.83% to $28.0 billion in 2023, then surged by 62.68% to $45.5 billion in 2024, then advanced by 23.35% to $56.1 billion in 2025.
• The last three Common Equity figures came in at $56.1 billion (Q3 2025), $45.5 billion (Q3 2024), and $28.0 billion (Q3 2023), per Business Quant data.